18435880. Methods and Systems for Analyzing Nucleic Acid Molecules simplified abstract (The Board of Trustees of the Leland Stanford Junior University)

Methods and Systems for Analyzing Nucleic Acid Molecules

Organization Name

The Board of Trustees of the Leland Stanford Junior University

Inventor(s)

David M. Kurtz of San Carlos CA (US)

Maximilian Diehn of San Carlos CA (US)

Arash Ash Alizadeh of San Mateo CA (US)

Methods and Systems for Analyzing Nucleic Acid Molecules - A simplified explanation of the abstract

This abstract first appeared for US patent application 18435880 titled 'Methods and Systems for Analyzing Nucleic Acid Molecules

Simplified Explanation

The patent application describes processes and materials for detecting cancer from a biopsy, including sequencing cell-free nucleic acids to detect sequences derived from a neoplasm.

• Cell-free nucleic acids can be sequenced to detect cancer.
• Detection of somatic variants can indicate the presence of cancer.
• Clinical intervention can be performed based on diagnostic scan results.

Potential Applications

The technology can be used in medical diagnostics to detect cancer at an early stage, allowing for timely clinical intervention.

Problems Solved

This technology helps in early detection of cancer, which can lead to better treatment outcomes and improved patient survival rates.

Benefits

- Early detection of cancer - Timely clinical intervention - Improved treatment outcomes

Potential Commercial Applications

The technology can be utilized by healthcare providers, diagnostic laboratories, and pharmaceutical companies for cancer detection and treatment monitoring.

Possible Prior Art

One possible prior art could be the use of next-generation sequencing technologies for cancer detection from biopsy samples.

Unanswered Questions

How cost-effective is this technology compared to existing methods for cancer detection?

Answer: The cost-effectiveness of this technology compared to existing methods needs to be further studied and evaluated to determine its economic feasibility for widespread adoption.

What are the potential limitations or challenges in implementing this technology in clinical settings?

Answer: The potential challenges in implementing this technology in clinical settings, such as regulatory approvals, data interpretation, and infrastructure requirements, need to be addressed for successful integration into routine medical practice.

Original Abstract Submitted

Processes and materials to detect cancer from a biopsy are described. In some cases, cell-free nucleic acids can be sequenced, and the sequencing result can be utilized to detect sequences derived from a neoplasm. Detection of somatic variants occurring in phase can indicate the presence of cancer in a diagnostic scan and a clinical intervention can be performed.